Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain
OwnerJulian Blagginventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of small molecule heterocyclic inhibitors of GTP cyclohydrolase (GCH-I), or a tautomer, prodrug, or pharmaceutically acceptable salt thereof. The invention also features pharmaceutical compositions of the compounds and the medical use of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, or neuropathic pain).
Claims54
A compound having a structure according to Formula (I):
- or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, wherein:
- R1, R2, R3, and R4 are each, independently, H, optionally substituted C1-6 alkyl, or R1 and R2, R2 and R3, or R2 and R4 combine to form a double bond,
- R5, R6, and R7 are each, independently, H or optionally substituted C1-6 alkyl, and
- wherein one and only one of R1 and R2, R2 and R3, or R2 and R4 combine to form a double bond, and
- when R5, R6, and R7 are H, R1 and R2 combine to form a double bond and R3 is H, or when R5, R6, and R7 are H, R2 and R3 combine to form a double bond and R1 is H, R4 is not —CH2C6H5, —CH2(p-C6H4—CN), —CH2(p-C6H4—CH3), —CH2CH═CH2, —CH2C(═O)-(p-C6H4-OMe), —CH2C(═O)NH-(o-C6H4-OEt), —CH2C(═O)NH-(2-methoxy-5-chloro-C6H3), —CH2C(═O)NH-(2-methylcyclohexyl), or —CH2C(═O)NH-(p-C6H4—SO2(azepane)).
A compound having a structure according to Formula (III):
- or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, wherein
- X1 is O or NR1;
- X2 is O or NR2;
- R1 and R2 are each, independently, selected from H, or optionally substituted C1-6 alkyl;
- R3 is H, halogen, or NR8R9, or R3 combines with R4 to form an oxo group;
- and
- R4 combines with R1 or R2 to form a C═N bond or R4 combines with R3 to form an oxo group;
- R5, R6, R7, R8, and R9 are each, independently, H or optionally substituted C1-6 alkyl;
- and
- when R5, R6, and R7 are H, X1 is NR1, R1 and R4 combine to form a C═N double bond, and X2 is NH, R3 is not H or NH2, and
- when R5, R6, and R7 are H, X1 is NH, R3 combines with R4 to form an oxo group, and X2 is NR2, R2 is not H.
A compound having a structure according to
- or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, or according to
- or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6, and R7 are each, independently, H or optionally substituted C1-6 alkyl.
A compound selected from the group consisting of:
- or a tautomer, prodrug, or pharmaceutically acceptable salt thereof,
- and
- or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, wherein each of R1, R6, and R7, is H or optionally substituted C1-6 alkyl.
A compound according to Formula (VI),
- or a tautomer, prodrug, or pharmaceutically acceptable salt thereof, wherein each of R1, R2, R6, and R7 is, independently, H or optionally substituted C1-6 alkyl.
Dependencies are inferred from the claim text.